SG10201906329VA - Prohemostatic proteins for the treatment of bleeding - Google Patents

Prohemostatic proteins for the treatment of bleeding

Info

Publication number
SG10201906329VA
SG10201906329VA SG10201906329VA SG10201906329VA SG10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA
Authority
SG
Singapore
Prior art keywords
bleeding
treatment
proteins
prohemostatic
subject
Prior art date
Application number
SG10201906329VA
Inventor
Daniël Verhoef
Pieter H Reitsma
Mettine H A Bos
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of SG10201906329VA publication Critical patent/SG10201906329VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING The present invention relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject. No suitable figure
SG10201906329VA 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding SG10201906329VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26

Publications (1)

Publication Number Publication Date
SG10201906329VA true SG10201906329VA (en) 2019-08-27

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding
SG10201906329VA SG10201906329VA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Country Status (25)

Country Link
US (4) US10537618B2 (en)
EP (2) EP3149163B1 (en)
JP (3) JP6640198B2 (en)
KR (2) KR102245264B1 (en)
CN (1) CN106536566A (en)
AU (2) AU2015268149B2 (en)
BR (1) BR112016027649A2 (en)
CA (1) CA2949349A1 (en)
DK (1) DK3149163T3 (en)
EA (2) EA202190813A1 (en)
ES (1) ES2813440T3 (en)
HR (1) HRP20201311T1 (en)
HU (1) HUE052098T2 (en)
IL (2) IL249132B (en)
LT (1) LT3149163T (en)
MA (2) MA40042B1 (en)
MX (2) MX2016015567A (en)
NZ (1) NZ727444A (en)
PL (1) PL3149163T3 (en)
PT (1) PT3149163T (en)
RS (1) RS60706B1 (en)
SG (2) SG11201609811TA (en)
SI (1) SI3149163T1 (en)
WO (1) WO2015183085A1 (en)
ZA (1) ZA201608017B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949349A1 (en) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
CN108486197B (en) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 Preparation method of high-purity edoxaban intermediate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
DK0574402T3 (en) 1990-11-26 1998-05-18 Chiron Corp Expression of PACE in Host Cells and Methods for Using Them
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (en) 1992-02-11 1993-08-12 Max Planck Gesellschaft ANTIDOT FOR HIRUDIN AND SYNTHETIC THROMBIN INHIBITORS
AT404357B (en) 1995-06-13 1998-11-25 Immuno Ag PROTHROMINE DERIVATIVES
DE19605126A1 (en) 1996-02-12 1997-08-14 Basf Ag Thrombin muteins as an antidote for thrombin inhibitors
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (en) * 2005-11-15 2016-02-05 Philadelphia Children Hospital METHODS AND COMPOSITIONS TO MODULATE HEMOSTASIA.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
CN103451172A (en) * 2007-04-13 2013-12-18 催化剂生物科学公司 Modified factor vii polypeptides and uses thereof
ES2849426T3 (en) * 2007-09-28 2021-08-18 Alexion Pharma Inc Antidotes for Factor Xa Inhibitors and Procedures for Using Them
TWI465247B (en) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
EA028865B1 (en) 2012-07-25 2018-01-31 Каталист Биосайенсиз, Инк. Modified factor x polypeptides and uses thereof
JP6437458B2 (en) 2013-01-31 2018-12-12 ファイザー・インク Compositions and methods for neutralizing factor Xa inhibition
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
CA2949349A1 (en) * 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding

Also Published As

Publication number Publication date
HRP20201311T1 (en) 2020-12-11
JP6640198B2 (en) 2020-02-05
KR102245264B1 (en) 2021-04-28
RS60706B1 (en) 2020-09-30
IL249132A0 (en) 2017-01-31
NZ727444A (en) 2021-12-24
US20200138917A1 (en) 2020-05-07
EA201692161A1 (en) 2017-08-31
KR20170020332A (en) 2017-02-22
DK3149163T3 (en) 2020-08-31
CA2949349A1 (en) 2015-12-03
EP3149163B1 (en) 2020-06-03
MA51688A (en) 2020-12-02
KR102351728B1 (en) 2022-01-14
SG11201609811TA (en) 2016-12-29
US20220288172A1 (en) 2022-09-15
AU2021203838B2 (en) 2023-03-02
US11304995B2 (en) 2022-04-19
IL249132B (en) 2020-09-30
EA202190813A1 (en) 2021-12-31
MA40042B1 (en) 2020-08-31
MX2016015567A (en) 2017-06-29
CN106536566A (en) 2017-03-22
US20170157223A1 (en) 2017-06-08
EP3744840A1 (en) 2020-12-02
US10537618B2 (en) 2020-01-21
IL277377A (en) 2020-11-30
HUE052098T2 (en) 2021-04-28
LT3149163T (en) 2020-09-25
JP2017522900A (en) 2017-08-17
ZA201608017B (en) 2019-04-24
WO2015183085A1 (en) 2015-12-03
SI3149163T1 (en) 2020-10-30
AU2015268149B2 (en) 2021-03-11
AU2021203838A1 (en) 2021-07-08
PT3149163T (en) 2020-09-03
JP2020062039A (en) 2020-04-23
EA037991B1 (en) 2021-06-21
JP2022134139A (en) 2022-09-14
ES2813440T3 (en) 2021-03-23
IL277377B (en) 2021-10-31
US20200138916A1 (en) 2020-05-07
PL3149163T3 (en) 2020-12-28
US11357836B2 (en) 2022-06-14
KR20210054573A (en) 2021-05-13
EP3149163A1 (en) 2017-04-05
BR112016027649A2 (en) 2017-08-15
AU2015268149A1 (en) 2016-12-08
MX2020013410A (en) 2021-02-26

Similar Documents

Publication Publication Date Title
PH12017501481A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2018007703A (en) Inhibitors of the menin-mll interaction.
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
EP3267792A4 (en) Compositions for use in treating pulmonary arterial hypertension
MX2021013665A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema.
EA201791775A1 (en) CYTESTINE PROTEASIS
MX2017016345A (en) Fusion proteins for inhibiting angiogenesis.
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA202090632A1 (en) METHODS AND COMPOSITIONS FOR TREATING DISORDERS WITH THE USE OF FALLISTATIN POLYPEPTIDES
EA201692552A1 (en) MODIFIED MENICOCCOKED POLYPEPTIDES fHbp
SI3197472T1 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
EA201790380A1 (en) MK2 INHIBITORS AND THEIR APPLICATIONS
EA201691429A1 (en) MODIFIED MENICOCCOKED POLYPEPTIDES fHbp
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006019A (en) Apilimod for use in the treatment of melanoma.
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
MX359029B (en) Method of treatment of hypoxia inducible factor (hif)-related conditions.
MX2020013410A (en) Prohemostatic proteins for the treatment of bleeding.
MX2018007468A (en) Collagen 7 compositions and methods of using the same.
PH12016501608A1 (en) Peptides and methods of use
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use
MX2018006479A (en) Recombinant serine proteases.